Gilead Says Sluggish Yescarta Business Will Continue To Fluctuate

 
• By Joseph Haas
  
Generate a summary of this article
Listen to this article
Beta

The CAR-T therapy’s sales declined 2% from the previous quarter, although EU sales are growing briskly. The HIV franchise posted its best quarter ever, but the company’s overall financial performance was flat.

business documents accounting with calculator and magnifying glass. concept for financial
Gilead's HIV franchise is flourishing, while cancer cell therapy is sluggish

Gilead Sciences Inc. expressed confidence in Yescarta’s overall commercial trajectory despite a slight downturn in sales from the previous quarter during its third quarter earnings call on 24 October. The chimeric antigen receptor T-cell (CAR-T) therapy brought in $118m during the July-through-September period, including $32m in the EU; the overall total was 2% below the second quarter, but up 57% year-over-year.

Departing chief financial officer Robin Washington pointed out that EU sales for Yescarta (axicabtagene ciloleucel) represented a 52% increase sequentially,...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Earnings

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.